Medicare Rx “Benefits”: Drug Industry, PBMs Expected To Prosper
Executive Summary
The possibility of a Medicare drug benefit leading to price controls is remote, Uwe Reinhardt, PhD, Princeton University, maintained during a Charles Schwab Capital Markets conference in Washington, D.C. Oct. 29
You may also be interested in...
Medicare Rx Benefit Costs Will Exceed $400 Bil. – Rep. Waxman
Medicare drug benefit legislation will ultimately cost well over the $400 bil. budget target, Rep. Henry Waxman (D-Calif.) predicted Oct. 29
PBMs, Pharmacies Can Cooperate To Defend Private Health Care, PCMA Says
Pharmacy benefit managers, retail pharmacies and drug manufacturers should work together to prevent government intervention in the health care industry, Pharmacy Care Management Association CEO Mark Merritt told the association's annual meeting Oct. 27 in Indian Wells, Calif
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011